Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M

Artiva Biotherapeutics, Inc.

71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.
FDA aligned on single Phase 3 registrational trial for AlloNK in ~150 refractory RA patients; ACR50 at 6 months primary endpoint.
Safety: no CRS, ICANS, or AlloNK-related discontinuations; outpatient administration in community rheumatology clinics.
Q1 net loss $23.5M; cash $86.8M expected to fund operations into Q2 2027.
ATM sales suspended under Sales Agreement with Leerink; agreement remains in effect.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Artiva Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Artiva Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Artiva Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-213239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.